Current and historical daily PE Ratio for PZRXQ (
PhaseRx Inc
) from 2016 to May 12 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. PhaseRx stock (PZRXQ) PE ratio as of May 12 2024 is 0.
More Details
PhaseRx Inc (PZRXQ) PE Ratio (TTM) Chart
PhaseRx Inc (PZRXQ) PE Ratio (TTM) Historical Data
View and export this data going back to 2016. Start your Free Trial
Total 0
- 1
| PhaseRx PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
PhaseRx Inc (PZRXQ) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
PhaseRx Inc
NAICS : 325412
SIC : 2834
ISIN : US71723F1030
Compare
Compare
Traded in other countries / regions
PZRXQ.USA IPO Date
2016-05-18Description
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers